A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
450actual
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-03 | actual | When the study began enrolling |
| Primary completion | 2025-06-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-30 | actual | The whole study's end, after follow-up |
| First posted | 2022-04-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Sclerosis, Relapsing-Remitting
Intervention
- Drug: Ozanimod
Primary outcome
what the primary-completion date above is the date OFProportion of participants persistence with therapy
measured Up to 36 months
Publications
- PMID 35832177 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed